GSK (LSE:GSK) Is Grappling With Suspected Counterfeit Antibiotics In Nigeria
What GSK (LSE:GSK)'s Cancer And HIV Trial Wins Mean For Shareholders
GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments
ViiV Healthcare Presents Real-World HIV Data Showing Higher Adherence and Treatment Persistence With Long-Acting Cabotegravir/Rilpivirine Injections
GSK (LSE:GSK) Stock Still Looks Below Fair Value Following Jemperli Approval
Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine
GSK (LSE:GSK) Wins FDA Nod For Jemperli As ESMO Data Builds Oncology Case
GSK: The Gas Pedal Is Still Down, But Bumps Ahead
Jefferies Downgrades GSK to Hold, Lowers Price Target to $55.9
GSK (LSE:GSK) Shares Dropped, So What Is Behind The Latest Attention?
Glaxo: Q3 Earnings Snapshot
What GSK (GSK) Said on Its Q3 Earnings Call
GSK Fumbles On Vaccines, HIV — Reversing An 11% Pre-Earnings Run
GSK plc (GSK) Q3 2026 Earnings Call Transcript
What GSK Needs to Do After Weak Vaccine Sales Spoil an Earnings Beat
GSK’s Specialty Drugs Grow by Double Digits While Vaccines Slip in a Q3 Beat
UPDATE: GSK Q3 Adj. EPS $1.47 Beats $1.40 Estimate, Sales $11.948B Beat $11.800B Estimate
GSK (GSK) Q3 Earnings and Revenues Beat Estimates
GSK Q3 2026 Earnings Call Transcript
Vaccines worries hit GSK
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.